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Background
Vitamin D deficiency is a common problem with implications for human health. 1 A large body of epidemiological evidence links vitamin D deficiency with a higher risk of cardiovascular disorders including hypertension. 2, 3 A meta-analysis of observational studies found that every 16 ng/ml decrement in vitamin D was associated with a 16% higher risk of hypertension. 4 A meta-analysis of population genetic studies suggested that polymorphisms related to lower vitamin D status were associated with higher blood pressure. 5 Additionally, low vitamin D concentrations have been shown to predict future hypertension among individuals with normal blood pressure at baseline. 2 Experimental work provides further evidence of a link between vitamin D status and blood pressure. Vitamin D receptors are expressed throughout the cardiovascular system on vascular smooth muscle, endothelium and cardiomyocytes. 6, 7 Disruption of these receptors in animals is associated with elevated blood pressure, which can be normalized with vitamin D administration. 8 These observations raise the possibility that vitamin D supplementation could reduce blood pressure in humans. However, results of randomized intervention trials have been conflicting, with some studies but not others suggesting a benefit. [9] [10] [11] [12] [13] [14] In most of the trials, blood pressure was not the primary endpoint nor was it measured using standardized protocols. These trials also typically randomized fewer than 150 participants and included a large proportion of individuals who were already on anti-hypertensive therapy. Importantly, very few non-white individuals have been included in prior studies, despite the high prevalence of both vitamin D deficiency and elevated blood pressure among minorities.
The absence of definitive data has led to calls for adequately-powered, prospective randomized trials of vitamin D supplementation and blood pressure. 15 Accordingly, we vitamin D status and blood pressure. Vitamin D receptors are expressed througho ho out ut t the he he cardiovascular system on vascular smooth muscle, endothelium and cardiomyocytes. 6, 7 Di Disr sr srup up upti ti tion on n o of f f th hes es ese e e receptors in animals is assoc c cia ia iate e ed with elevat ted ed e blo lo ood od od pressure, which can be n norm m rmalized wit ith h h v vi ita ami m m n n n D D D ad ad adm mi mini ni nist st stra rat tio o on. 8 8 8 Th Thes es ese e e ob obse e erv rva at tio o ons ns rai ai a se e e t t the he he p po o ossi si sibi bi bil l lity ty y t th h hat at v vit it tam m min in in D D D s su up uppl pl plem em emen n nta tati ti tion on n c cou ou oul ld r r red d duc uce e e blood pressu ure re e i i in n hu hu huma ma m ns n n . H H How ow wev ev ever er er, , re re resu su ult lt ts s s of of of r ran an ando do domi mi mize ze zed d d in in inte te terv rv r en en enti ti tion on on t t tri ri rial al a s s s ha ha have ve ve b b bee e n by guest on April 14, 2017 http://circ.ahajournals.org/ Downloaded from conducted the DAYLIGHT study, a multicenter randomized trial of vitamin D supplementation in a racially-diverse sample of individuals with low vitamin D stores and elevated blood pressure.
Methods

Study design
DAYLIGHT was a double-blind, multicenter, 6-month randomized trial of high (4,000 IU per 
Inclusion and Exclusion criteria
The study enrolled participants between 18 and 50 years of age who had an averaged mean systolic blood pressure between 120 and 159 mm Hg and a diastolic blood pressure less than 99 mm Hg at two clinic visits. The other main inclusion criterion was a 25-hydroxyvitamin D level of 25 ng/ml or below at the screening visit.
Individuals were excluded if they had use of any anti-hypertensive medication in the past 
Vitamin D supplementation
Vitamin D was administered using once-daily oral doses of vitamin D 3 (cholecalciferol), with a total of 4,000 IU or 400 IU, in the high-dose and low-dose arms, respectively. Administration was via gravity-metered dropper bottles to deliver a consistent dosage (D Drops, Canada). Two drops (each containing 200 IU or 2000 IU of vitamin D) were taken orally once-daily.
Compliance was assessed by weighing bottles on a calibrated, gravimetric scale at each study visit. Participants were not given calcium supplementation, however they were given a lifestyle changes document with advice on optimal calcium intake.
Participants were assigned to a vitamin D dose in accordance with the randomization schedule. Block randomization in units of 10 was done to confirm an equal distribution of vitamin D doses within sites. Participants and study staff were blinded to treatment allocation and to the results of any 25-hydroxyvitamin D test performed after the screening visit.
Blood pressure monitoring
Follow-up visits occurred every 2 months after the randomization visit until the end of the study.
At every study visit, blood pressure was measured 4 times using a validated digital blood pressure monitor (HEM-907X [Omron Healthcare, Inc, Banncockburn, IL]) and was averaged across the final 3 measurements. In addition, at baseline and 6 months, 24-hour ambulatory blood pressure data was collected using a 24-hour ambulatory monitor (Spacelabs Healthcare, Issaquah, WA) with an appropriately-sized cuff. The protocol for clinic and 24-hour ambulatory blood pressure monitoring was standardized across all sites and details are in the Supplementary visit. Participants were not given calcium supplementation, however they were g g giv iven e e a a a l l lif if ifes es esty tyle changes document with advice on optimal calcium intake. Material.
Monitoring
Blood samples were shipped to a central laboratory (Esoterix Clinical Lab Services, LabCorp, Cranford, NJ). Laboratory measurements were obtained every study visit and included plasma calcium, phosphorus, creatinine, aspartate and alanine aminotransferases and serum 25-hydroxyvitamin D levels. We used a direct competitive chemiluminescence immunoassay (DiaSorin Inc, Stillwater, MN) for quantitative determination of total 25-hydroxyvitamin D in serum. 16 The intra and interassay coefficient of variation was less than 5 and 10 percent respectively (assay range 4-150 ng/ml). Study data were reviewed by an external Data and Safety Monitor during and at the completion of the study.
Endpoints and sample size estimates
The primary end point of the study was the change in mean 24-hour ambulatory systolic blood pressure. The secondary endpoints of the study included the change in mean 24-hour ambulatory diastolic blood pressure, daytime and nighttime ambulatory blood pressure, clinic blood pressure and pulse pressure, and the relation of vitamin D status to change in clinic and 24-hour ambulatory blood pressures.
Sample size estimates were based on data for the standard deviation of the change in 24-hour ambulatory systolic blood pressure from previous studies. 17 We powered the study to detect a 3 mm Hg difference in the primary endpoint. In order to achieve this power, we originally targeted a sample size of 450 randomized individuals. Because we enrolled a young and asymptomatic study population, we incorporated the assumption of a 20% dropout rate.
With 20% dropout, we estimated that we would have 80% power to detect a 2.8 mm Hg difference in the primary endpoint. With twice the dropout rate, our minimum detectable Safety Monitor during and at the completion of the study. t In September 2011, after 160 participants had been randomized, the investigators were notified by the D Drops Company that random lot testing indicated that up to 40 participants in the high-dose arm had received a mean dose of 2,000 IU per day, rather than 4,000 IU per day.
After informing the Institutional Review Board and the FDA, a new lot was established, and vitamin D bottles for existing subjects were replaced. Blinding was maintained throughout the change. Concentration stability was confirmed during the remainder of the study. The target sample size was raised by 80 subjects, from 450 to 530 participants, in order to offset any potential reduction in power from the 40 participants in the high-dose arm who may have received the reduced dose. All analyses were conducted by the intention-to-treat principle, with planned secondary analyses stratified by vitamin D lot (e.g. before or after September 2011).
Statistical Analyses
Demographics and baseline characteristics for randomized subjects were summarized by calculating median and inter-quartile range (IQR) for continuous variables and percentages for categorical variables. The bivariate comparisons between groups were performed with the use of the Wilcoxon rank sum test or chi-square test. To model the change in mean 24-hour systolic blood pressure, we used an ordinary least squares model that included treatment group as the main effect, with adjustment for race, study site, randomization season, and baseline blood pressure. A race by randomization interaction term was also included in the model to test whether treatment effects differed by race. In secondary analyses, we repeated the analysis by using the most recent clinic blood pressure to impute missing values for mean 24-hour ambulatory blood pressure. We fit a generalized ordinary least square model for each secondary potential reduction in power from the 40 participants in the high-dose arm who m m may y y ha ha have e ve eceived the reduced dose. All analyses were conducted by the intention-to-treat principle, with pl lan an nne ne ned d d se se eco co c n n ndar ar ry y y a analyses stratified by vitamin n n D D lot (e.g. before re e or af af aft te ter September 2011).
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Results
A total of 1,343 individuals were screened for eligibility across all sites. We randomized 534 eligible individuals (Figure 1 ). The mean age was 36 ± 10 years, 62% were men, and 56% were non-white. The mean 25-hydroxyvitamin D level was 15.7 ± 6.3 ng/ml, with nearly threequarters of the study sample (73%) below 20 ng/ml. There were no significant differences between the high-dose and low-dose vitamin D arms in any of the clinical or demographic characteristics ( Table 1) .
The initial clinic blood pressure was in the hypertensive range ( 140/90 mm Hg) for 28% of study participants. A 24-hour ambulatory blood pressure measurement was available on all subjects at baseline. As expected, mean ambulatory systolic and diastolic blood pressures were slightly lower than the corresponding clinic blood pressures, which was largely attributable to lower blood pressures at night ( Table 1) . 
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The in in nit it i ia ia i l l l cl cl clin in nic ic c blo lo lood od od p p pre re ress ss sur u u e e e wa wa was s s in in in t t the he h h hyp yp y er er erte te tens ns nsiv iv ve e e ra r r ng ng nge e e ( ( ( 14 14 The results of pre-specified subgroup analyses are shown in Figure 5 for the primary endpoint. These analyses revealed no evidence of heterogeneity in the study results. Analyses stratified by enrollment before or after September 2011 also showed no difference in the results.
Lastly, we repeated the analysis for the primary endpoint using clinic blood pressures to impute missing values for 24-hour ambulatory blood pressure at 6 months. This analysis yielded similar results to the primary analysis, with no significant difference in 24-hour systolic blood pressure between the high-dose and low-dose arms (p=0.99).
The mean drop usage was 96% and 97% in the high-dose and low-dose vitamin D arms, respectively, based on bottle weights. There was no significant difference in multivitamin use or body mass index between the high-dose and low-dose arms. Plasma calcium, creatinine, phosphorus, and transaminase levels did not differ between the high-dose and low-dose vitamin D arms at 6 months. Four individuals were noted to have an elevated calcium level (>10.5 mg/dl) during the study (3 in the high-dose arm, 1 in the low-dose arm). Two subjects (1 in each arm) were noted to have a phosphorus level >5 mg/dl. There were no serious adverse events reported. The incidence of adverse events did not differ between the high-dose and low-dose endpoint. These analyses revealed no evidence of heterogeneity in the study res su u ults ts s. A A Ana na naly ly lyse se s s s tratified by enrollment before or after September 2011 also showed r no difference in the results.
La ast st stly ly ly, , we we e r r rep ep pea ate te u ubs bs sta t ntial hete ter ro og g gene ne eity y y am am amon on ong g th th the e e st stud ud dies in n nclud de e ed i in n n th the e V Vi Vim mal le esw swa a ara an an m m me et eta-a-an an anal al a ys ys sis s s, , wi wi with h h on nly ly ly 1 1 1 o of f mo mo more re t tha ha han n 3 30 0 c c coh ohor r rts ts s s sho ho howi wi w n ng ng a a a s s st t tati ti ist st s ic ic cal al lly ly sig ig igni ni nifi fica ca can nt nt as as asso so s c c cia at atio ion n n b be betw tw wee ee een "synthesis" va va ari ri rian an nts ts ts a and nd nd sys ys ysto to toli ic c c b b blo lo ood od d p p pre re ress ss ssur ur ure. e. e Fu Fu Furt rt r he he er, r r t t the he he co co coho ho h rt rt rts s s we we were re re r rou ou ugh gh ghly ly ly e e eve v nly split quarters had a level below 20 ng/ml. In contrast, prior trials often included individuals with 25-hydroxyvitamin D levels above 30 ng/ml. 9 Furthermore, we focused on individuals with untreated pre-hypertension or stage I
hypertension. Experimental studies suggest that the effect of vitamin D on blood pressure may be blunted by anti-hypertensive therapy, particularly agents that block the renin-angiotensin system. 18 The study was designed to minimize confounding by concomitant medications, in a colleagues, subjects were taking a median of 2 anti-hypertensive medications, and more than 40 0% % % w we were re e o o on n an n a a an ng ngiotensin-converting enzyme e e i i inh nh hibitor or angi iot o o en nsi si sin n n re r ceptor blocker. Whether the formulation of cholecalciferol influences bioavailability is not well established.
Though we cannot exclude the possibility that even higher levels of vitamin D than those achieved in DAYLIGHT would be needed to impact blood pressure, there is no biological basis for postulating such a threshold effect. In addition, the observational studies that motivated DAYLIGHT document a linear relationship with blood pressure across the range of vitamin D levels observed in the trial. 4 Lastly, even in the subset of individuals who attained 25-hydroxvitamin D levels above 50 ng/ml, there was no evidence of a trend toward lower blood pressures (Supplementary Figure 1) .
Approximately 20% of participants failed to complete the required follow-up visits, and an additional 10% were withdrawn early for meeting one of the exclusion criteria. High dropout rates are frequently seen in trials of vitamins or supplements. For instance, in the recentlycompleted TACT trial, 46% of subjects discontinued their multivitamin, with the most commonly cited reason being lack of interest in continuing vitamin therapy. 22 Adherence to a study medication may be particularly challenging for individuals who are young and asymptomatic, such as those enrolled in DAYLIGHT.
Because the likelihood of dropout was incorporated in the original power estimates, subject dropout had only a marginal impact on the final statistical power. The trial was designed to detect a difference in the primary endpoint of 3 mm Hg with 80% power. Post hoc calculations using the final sample size indicate a detectable difference of 3.1 mm Hg with 80% power. Furthermore, there was no evidence that individuals who completed the study differed from those who did not, with regard to baseline blood pressure or demographic characteristics. It is also noteworthy that analyses of clinic blood pressure, which included up to 455 subjects and provided even greater statistical power, yielded very consistent findings to those of the primary an additional 10% were withdrawn early for meeting one of the exclusion criteria ia a. H H Hig ig igh h h dr dr drop op o ou o t ates are frequently seen in trials of vitamins or supplemen n ts. For instance, in the recentlyco omp mp mple le let te ted d d TA TA TACT CT T t t tri rial, 46% of subjects disconti inu nu n e e ed their multivi vi ita t mi mi in, n, n w with the most co om mm mmonly cit ted ed d re e easo so on n be be bein in ing g g l la lack ck k o o of f i in nt t teres s st i in co on n ntin n nui ui ing ng g v vit itam am mi in n t the he hera a apy py y. 22 As with all randomized trials, the generalizability of our results to populations not studied is uncertain. For instance, we cannot exclude the possibility that vitamin D supplementation would have been more effective in individuals with greater degrees of hypertension or on baseline anti-hypertensive therapy. Nonetheless, there is no evidence from experimental or epidemiologic studies to suggest a mechanism by which vitamin D supplementation would only be effective in the context of existing anti-hypertensive medications. Nearly a third of our subjects had baseline blood pressures in the hypertensive range, and the remaining two-thirds were "pre-hypertensive," a group with high rates of progression to overt hypertension and increased cardiovascular risk. 24, 25 It is possible that concomitant calcium supplementation may be required to see antihypertensive effects from vitamin D therapy. We delivered a standard set of dietary guidelines to participants in both arms, which included recommendations regarding calcium intake.
uggesting that vitamin D has neutral effects on blood pressure irrespective of ra ac c ce o o or ba ba base se seli li line ne n vitamin D status.
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We did not include a placebo arm in this trial, instead administering 400 IU of cholecalciferol per day to subjects in the control arm, e.g. equivalent to the amount of vitamin D found in a typical multivitamin. During the design of DAYLIGHT, the Institutes of Medicine released guidelines regarding the recommended dietary intakes of vitamin D, which was 600 IU per day (from all sources) for the age group included in the trial. Because vitamin D deficiency was an inclusion criterion for DAYLIGHT, the investigators felt that it would be difficult to justify omission of vitamin D supplementation entirely from the control arm, particularly as participants were discouraged from taking out-of-study supplementation during the trial.
We cannot exclude the possibility that the vitamin D preparation in the low-dose arm had modest effects on blood pressure, attenuating our ability to detect a difference in the overall endpoint. Nonetheless, we observed minimal to no change in blood pressure in the high-dose Values are mean ± SD (median, IQR); SD: standard deviation; IQR: interquartile range; BP: blood pressure. * For clinic blood pressures, p values are based on generalized ordinary least square regression, with the following covariates: baseline blood pressure, study site, days from randomization, randomization arm, and randomization arm by days from randomization interaction. For daytime and nightime blood pressures, p values are based on ANCOVA, adjusted for race/ethnicity, study site, randomization season, and baseline blood pressure. A race by randomization group term was also included in the ANCOVA model. 1 118 18 18 , , , 11 11 1 2 2 2 -12 2 26) 6) 6) 11 11 119 9 9 ± ± ± 10 0 0 ( ( (11 11 118, 8, 8, 1 1 113 13 --1 1 126 26 26) months or planned use in the next 6 months; unwillingness or inability to comply with study requirements; or inability to provide informed consent.
Blood pressure monitoring
Clinic blood pressure was measured three times in the non-dominant arm with a validated digital blood pressure monitor (HEM-907X [Omron Healthcare, Inc, Banncockburn, IL]) and appropriately sized cuff. The average systolic and diastolic blood pressure was calculated from the last two measurements. Ambulatory blood pressure measurements were taken every 20
minutes from 0600-2200 h and every 30 minutes from 2200-0600 h. Daytime was defined as 0600-2159 h and nighttime was defined as 2200-0559 h. Thus, the maximum total number of analyzable measurements was 64, with 48 daytime and 16 nighttime measurements. The same ambulatory blood pressure device was used at baseline and follow up for each study participant.
If fewer than two-thirds of daytime (<33 measurements) or nighttime (<11 measurements) measurements were accurately recorded, the subject was asked to repeat the 24-hour monitoring procedure. Clinic and ambulatory blood pressure measurements were done in accordance with the American Heart Association guidelines.
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Early termination
Participants were discontinued from the protocol if they developed hypercalcemia (calcium > 10.5 mg/dl) or hyperphosphatemia (phosphorus > 5 mg/dl), or if 25-hydroxyvitamin D levels exceeded 100 ng/ml. Other reasons for early termination included failure to complete required visits, non-compliance with study medication (as defined by estimated drops dispensed < 80% or >120% of the target), or elevated blood pressure. The thresholds for early termination due to blood pressure were a systolic > 159 mm Hg or diastolic > 99 mm Hg at 2 consecutive study visits, or systolic > 169 mm Hg or diastolic > 109 mm Hg at any study visit. In addition, if anti- 
